Cytogenetic and clinical risk factors for assessment of ultra high-risk multiple myeloma

Leukemia Research
Junling ZhuangDaobin Zhou

Abstract

Cytogenetic assessments can improve conventional clinical risk assessment for ultra-high risk (UHR) multiple myeloma (MM) patients. Cytogenetic and clinical risk factors were examined in UHR MM patients. Consecutive MM patients (n = 168) were retrospectively screened for untreated, symptomatic MM between July 2008 and March 2011, including UHR (n = 35) and control (n = 60) patients with ≤ 12 or >12 month survival, respectively. Treatment outcomes; clinical, radiological, histological factors; and fluorescence in situ hybridization (FISH)-indicated cytogenetic abnormalities (CAs) were compared. Included UHR patients exhibited lower median overall survival (OS) (5 vs. >24 months); overall response rates (ORRs) (31.4% vs. 83.3%); complete response (CR), near CR (nCR), or very good partial response (VGPR) (8.6% vs. 51.7%) (all P<0.001); and partial response (PR) (22.9% vs. 31.7%, P = 0.358). UHR patients exhibited more renal failure (54.3% vs. 28.3%), hypercalcemia (11.4% vs. 0), elevated lactate dehydrogenase (LDH) (25.7% vs. 5%), secondary plasma cell leukemia (14.3% vs. 0), International Staging System (ISS) stage III (77.1% vs. 45%), and 1q21+ and 17p- (42.9% vs. 18.3%; 17.1% vs. 3.3%) (all P<0.05). ≥ 3 CAs indicated poor survi...Continue Reading

References

Apr 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip R GreippJan Westin
Sep 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P Leif Bergsagel, W Michael Kuehl
Mar 31, 2006·The New England Journal of Medicine·Robert A KyleL Joseph Melton
May 27, 2006·Blood·Fenghuang ZhanJohn D Shaughnessy
Jun 30, 2006·The New England Journal of Medicine·Ruth Collins-Nakai
Aug 2, 2008·Blood·Bruno PaivaUNKNOWN GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Grou
May 21, 2009·Seminars in Musculoskeletal Radiology·Andrea Baur-Melnyk, Maximilian F Reiser
Jun 19, 2009·The New England Journal of Medicine·Jean-Luc Harousseau, Philippe Moreau
Jul 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hervé Avet-LoiseauJean-Luc Harousseau
Sep 9, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Heinz LudwigNiklas Zojer
Jan 18, 2011·Hematology·Hervé Avet-Loiseau
Feb 5, 2011·Blood·Nikhil C MunshiUNKNOWN International Myeloma Workshop Consensus Panel 2
Sep 10, 2011·Clinical Lymphoma, Myeloma & Leukemia·Maria GkotzamanidouMeletios A Dimopoulos
Oct 19, 2011·International Journal of Hematology·Prashant Kapoor, S Vincent Rajkumar
Dec 20, 2011·American Journal of Hematology·S Vincent Rajkumar
Mar 3, 2012·Journal of Experimental & Clinical Cancer Research : CR·Francesco PisaniUNKNOWN Multiple Myeloma GIMEMA-Latium Region Working Group, Italy
Apr 25, 2012·Hematology·Jesus F San MiguelRamón Garcia-Sanz
Dec 5, 2012·British Journal of Haematology·Caterina MusolinoSebastiano Gangemi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.